Ms. Kopreski et al., DETECTION OF MUTANT K-RAS DNA IN PLASMA OR SERUM OF PATIENTS WITH COLORECTAL-CANCER, British Journal of Cancer, 76(10), 1997, pp. 1293-1299
Increased understanding of the molecular basis of colorectal cancer an
d recognition that extracellular DNA circulates in the plasma and seru
m of cancer patients enables new approaches to detection and monitorin
g. We used a polymerase chain reaction (PCR) assay to demonstrate muta
nt K-ras DNA in the plasma or serum of patients with colorectal cancer
, Plasma or serum was fractionated from the blood of 31 patients with
metastatic or unresected colorectal cancer and from 28 normal voluntee
rs. DNA was extracted using either a sodium chloride or a gelatin prec
ipitation method and then amplified in a two-stage PCR assay using sel
ective restriction enzyme digestion to enrich for mutant K-ras DNA. Mu
tant K-ras DNA was detected in the plasma or serum of 12 (39%) patient
s, all confirmed by sequencing, but was not detected in any of the nor
mal volunteers, K-ras mutations were detected in plasma or serum regar
dless of sex, primary tumour location, principal site of metastasis or
proximity of chemotherapy and surgery to blood sampling. Tumour speci
mens available for 19 of the patients were additionally assayed for ra
s mutations and compared with blood specimens. Our results indicate mu
tant K-ras DNA is readily detectable by PCR in the plasma or serum of
patients with advanced colorectal cancer, Thus, plasma-or serum-based
nucleic acid amplification assays may provide a valuable method of mon
itoring and potentially detecting colorectal cancer.